The study provides so far the most comprehensive multi-omics analysis of mucosal and tumor samples from colorectal cancer patients. The prospective study supports a previously suggested role for the gut microbiota in clinical outcomes in patients undergoing primary resection for colorectal carcinoma, independent of variables such as AJCC stage, tumor location, and adjuvant therapy. Tumor–microbiota co-metabolites, which warrant further investigation as potential mediators of disease outcome were also discovered. Future studies should focus on establishing mechanisms through which communities of colorectal carcinoma- and mucosa-associated commensals, and their metabolic output, might influence determinants of patient prognosis, including immune surveillance.
Link to the article:https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-023-01518-w
